Top

BMC Women's Health

Published in:

Open Access 01-12-2019 | Metronidazole | Research article

Secnidazole for treatment of bacterial vaginosis: a systematic review

Authors: Mohamed A. Abd El Aziz, Foruzan Sharifipour, Parvin Abedi, Shayesteh Jahanfar, Helen Marie Judge

Published in: BMC Women's Health | Issue 1/2019

Abstract

Background

Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV.

Methods

The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3.

Results

Our search found six trials involving 1528 participants. Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89–14.60, p < 0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51–14.84, p = 0.0.008). Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30–25.33, p = 0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06–382.45, p = 0.05). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole.

The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole.

Conclusion

This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g. Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.

Available only for authorised users

Gibbs RS, Karlah BY, Haney AF, Nygaard IE. Danforth’s Obstetrics and Gynecology .10^th edi. 2008 Lippincott Williams and Wilkins. Philadelphia. PA19106 USA:p.625–640.

Biggs WS, Williams RM. Common gynecologic infections. Prim Care 2009;36(1):33–51, viii. doi: https://doi.org/10.1016/j.pop.2008.10.002.PubMedCrossRef

Terraf M, Tomás J. Nader - Macías M, Silva C. screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components. J Appl Microbiol. 2012;113(6):1517–29.PubMedCrossRef

Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States association with symptoms sexual behaviors and reproductive health. Sex Transm Dis. 2007;34(11):864–9.PubMedCrossRef

Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women,” Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006055. doi: https://doi.org/10.1002/14651858. CD006055.pub2.

Li XD, Tong F, Zhang XJ, Pan WJ, Chen ML, Wang CC, Li X, et al. Incidence and risk factors of bacterial vaginosis among pregnant women: a prospective study in Maanshan city, Anhui Province, China. J Obstet Gynaecol Res. 2015 Aug;41(8):1214–22. https://doi.org/10.1111/jog.12704.PubMedCrossRef

Armstrong NR , Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health 2009 Agust;1(9):59–65.

Bacterial vaginosis - CDC fact sheet. (2017, February 16). Retrieved from https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm. Accessed 16 Feb 2017.

Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis. 2009;199(5):680–3.PubMedPubMedCentralCrossRef

10.

Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis - limitations and need for innovation. J Infect Dis. 2016;214(Supp l):S14–20.PubMedPubMedCentralCrossRef

11.

CDC. Sexually transmitted disease treatment guidelines. MMWR. 2015;64:1–137.

12.

Sobel JD, ed. Bacterial Vaginosis. Waltham, MA: UptoDate 2013. Available at: www.uptodate.com/contents/bacterialvaginosis?topicKey=OBGYN%2F5451&elap Accessed 6 April 2017.

13.

Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole. Infect Dis Obstet Gynecol. Volume 2010, Article ID 705692, 6 pages. https://doi.org/10.1155/2010/705692 CrossRef

14.

Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978;54:77–80.

15.

Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65:462–73.PubMedCrossRef

16.

Núñez JT, Gómez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2005;88:281–5.PubMedCrossRef

17.

Hillier S, Nyirjesy P, Waldbaum A, Schwebke J, Morgan F, Adetoro N, Braun C. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017;130(2):379.PubMedCrossRef

18.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ online 2009;339 b2700.PubMedPubMedCentralCrossRef

19.

Higgins, J., D. Altman, et al.. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. J. Higgins and S. Green, Version 5.1.0 (updated 2011). The Cochrane Collaboration 2011.

20.

Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017, 217;(6):678.e1–9. https://doi.org/10.1016/j.ajog.2017.08.017.PubMedCrossRef

21.

Thulkar J, Kriplani A, Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012 Mar-Apr;44(2):243–5. https://doi.org/10.4103/0253-7613.93859.PubMedPubMedCentralCrossRef

22.

Saraçoğlu F, Göl K, Sahin I, Türkkani B, Atalay C, Oztopçu C. Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole. Int J Gynaecol Obstet. 1998;62(1):59–61.PubMedCrossRef

23.

Wang FM, Qian XD, Xu H, Yu HY. Efficacy of 5-nitroimidazole derivatives in treatment of bacterial vaginosis. Zhonghua Yi Xue Za Zhi. 2008 Aug 12;88(31):2201–3.PubMed

24.

Tariq N, Basharat A, Khan DH, Fahim A, Khan MH. Treatment for Symptomatic Bacterial Vaginosis: ARandomized Controlled Trial. J Coll Physicians Surg Pak. 2017;27(11):686–9 2743.PubMed

25.

401. Nct. A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis. 2015. Https://clinicaltrials.gov/show/nct02418845. Accessed 30 Mar 2016.

26.

Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of Secnidazole 2 g for the treatment of women and Postmenarchal adolescent girls with bacterial Vaginosis. J Women’s Health (Larchmt). 2018 Apr;27(4):492–7. https://doi.org/10.1089/jwh.2017.6500.CrossRef

27.

Tolosa JE, Chaithongwongwatthana S, Daly S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol. 2006;195:1198.PubMedCrossRef

28.

Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761.PubMedCrossRef

29.

Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in south African women: a nested case-control study. J Infect Dis. 2005;192:1372.PubMedCrossRef

30.

Amaya-Guio J, Viveros-Carreno DA, Sierra-Barrios EM, Martinez-Velasquez MY, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701.PubMed

31.

Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018:13(5). https://doi.org/10.2217/fmb-2017-0270.PubMedCrossRef

32.

Nagel JL, Aronoff DM. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 8^th Edi; 2015.

33.

SOLOSEC (secnidazole) oral granules Initial U.S. Approval: 2017: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf. 2017.

34.

Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158:819.PubMedCrossRef

35.

Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899.PubMedCrossRef

Title: Secnidazole for treatment of bacterial vaginosis: a systematic review
Authors: Mohamed A. Abd El Aziz
Foruzan Sharifipour
Parvin Abedi
Shayesteh Jahanfar
Helen Marie Judge
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Metronidazole
Published in: BMC Women's Health / Issue 1/2019
Electronic ISSN: 1472-6874
DOI: https://doi.org/10.1186/s12905-019-0822-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Secnidazole for treatment of bacterial vaginosis: a systematic review

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Correlates of regret with treatment decision-making among Japanese women with breast cancer: results of an internet-based cross-sectional survey

Menstrual disorders in amateur dancers

Effectiveness of a culturally tailored SMS alcohol intervention for same-sex attracted women: protocol for an RCT

Sexual risk behavior and substance use among young, diverse women seeking care at a reproductive health clinic

Using the health belief model to assess beliefs and behaviors regarding cervical cancer screening among Saudi women: a cross-sectional observational study

The psychometric properties of the Barkin index of maternal functioning (BIMF) for the Iranian population